Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Novartis sees start of $2B dermatology opportunity with new EU Xolair approval

07.03.2014 / Fierce Pharma

On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives–the first such product cleared there for patients who don't respond to antihistamines alone.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: